ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Event‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
High‐dose chemotherapy followed by autologous haematopoietic cell… showed no clear difference in event‐free survival (reported as number of participants with… compared with conventional chemotherapy plus whole lung irradiation (low certainty).
1 finding from 1 review
Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Mortality at latest · preterm or low birth weight infants
1 finding from 1 review
Neurodevelopmental disability · preterm or low birth weight infants
1 finding from 1 review
Hyponatraemia (< 130 mmol/L) · preterm or low birth weight infants
1 finding from 1 review
Hypernatraemia (≥ 150 mmol/L) · preterm or low birth weight infants
It is very uncertain whether early and late (day 1 to 28 after birth) higher changes hypernatraemia (≥ 150 mmol/L) compared with lower sodium intake (very low certainty).
1 finding from 1 review
Postnatal growth failure (weight < 10th percentile) · preterm or low birth weight infants
1 finding from 1 review
Necrotising enterocolitis · preterm or low birth weight infants
1 finding from 1 review
Chronic lung disease · preterm or low birth weight infants
1 finding from 1 review
Any cancer risk No. of participants: 19,475 (3 RCTs) · Participants in trials with low risk of bias
Highest showed no clear difference in any cancer risk No. of participants: 19,475 (3 RCTs) compared with lowest selenium exposure (high certainty).
1 finding from 1 review
Cancer mortality risk No. of participants: 17,448 (1 RCT) · Participants in trials with low risk of bias
Highest showed no clear difference in cancer mortality risk No. of participants: 17,448 (1 RCT) compared with lowest selenium exposure (high certainty).
1 finding from 1 review
Colorectal cancer risk (16 studies) · Participants in trials with low risk of bias
Highest showed no clear difference in colorectal cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).
1 finding from 1 review
Non‐melanoma skin cancer risk No. of participants: 2027 (2 RCTs) · Participants in trials with low risk of bias
Highest showed no clear difference in non‐melanoma skin cancer risk No. of participants: 2027 (2 RCTs) compared with lowest selenium exposure (moderate certainty).
1 finding from 1 review
Lung cancer risk (17 studies) · Participants in trials with low risk of bias
Highest showed no clear difference in lung cancer risk No. of participants: 19,009 (2 RCTs) compared with lowest selenium exposure (high certainty).
1 finding from 1 review